Should I stop taking my apixaban or rivaroxaban because of this?

No. This regulatory change affects how hospitals manage rare, life-threatening bleeding events — not the safety or efficacy of your anticoagulant for its approved use. Continue your prescribed dose and raise any concerns with your GP or specialist at your next appointment.

What happens if I have a serious bleed while on apixaban or rivaroxaban?

Hospitals have non-specific reversal options, primarily four-factor prothrombin complex concentrate (4F-PCC), which has been used for DOAC-related bleeding reversal and remains in clinical use. The 2024 CATAG assessment noted that andexanet alfa's clinical advantage over 4F-PCC was not established. Emergency departments remain equipped to manage these situations.

ANDEXXA delisted: Australia loses its only specific Factor Xa reversal agent

What just changed

On 20 May 2026, ANDEXXA (andexanet alfa) was removed from the Australian Register of Therapeutic Goods. It was the only agent on the ARTG specifically approved for reversing the anticoagulant effect of the direct oral Factor Xa inhibitors — apixaban (Eliquis) and rivaroxaban (Xarelto) — in adults with life-threatening or uncontrolled bleeding.

The TGA provisionally approved ANDEXXA in July 2023, conditional on a confirmatory randomised controlled trial verifying that the benefits outweigh the risks compared to usual care. When that confirmatory trial data was submitted, it was not sufficient to support full registration. The provisional registration was allowed to lapse.

This matters. Approximately one in five Australians over 75 is now on a direct oral anticoagulant. Apixaban and rivaroxaban together account for the vast majority of that prescribing. The rare but high-stakes scenario — a major intracranial haemorrhage, or life-threatening gastrointestinal bleed, in a patient taking one of these medicines — is precisely what andexanet alfa was designed for. Australia now has no ARTG-approved specific reversal agent for that scenario.

If you are on one of these medications and heard this news and felt a jolt: that response makes sense. It is also worth unpacking carefully.

The both-and

Two things are simultaneously true here, and they pull in opposite directions.

The first: andexanet alfa was always a complicated case. Australian Prescriber’s review noted that the drug’s high cost and uncertain clinical benefits — compared to current management with four-factor prothrombin complex concentrate (4F-PCC) — made its place in treatment uncertain. The 2024 CATAG assessment reached the same conclusion. The head-to-head data between andexanet alfa and 4F-PCC never materialised in a clean randomised format — a point that ultimately underpinned the TGA’s decision not to grant full registration. Andexanet alfa produced reliable reversal of anti-Factor Xa activity on a surrogate marker, but clinical superiority over what hospitals were already doing was not established to the standard required.

The second: 4F-PCC is not an equivalent substitute on paper. Andexanet alfa was specifically designed to bind and neutralise apixaban and rivaroxaban at the molecular level. Studies comparing the two agents in real-world intracranial haemorrhage populations show broadly similar haemostatic outcomes and thrombotic complication rates — but these are observational, retrospective, propensity-score analyses, not randomised trials. The absence of a confirmed superiority signal for andexanet alfa does not mean it was no better than 4F-PCC. It means the evidence was not strong enough to prove it was.

For the practising emergency physician or neurologist, this is a real clinical change. Andexanet alfa, even under provisional approval, was available for use in Australian hospitals and had specific reversal data that 4F-PCC does not. That specific agent is now gone from the ARTG.

2 cents

For the person on apixaban or rivaroxaban reading this: stop before you taper your dose or skip your tablets.

The risk that drove your anticoagulation prescription — atrial fibrillation reducing stroke risk, management of a DVT or pulmonary embolism — remains real and unchanged. Anticoagulants prevent catastrophic events far more often than they cause them. The regulatory status of a reversal agent is a question for your hospital’s emergency team, not a reason to alter your daily regimen unilaterally.

What this does mean, practically, is worth raising with your GP or specialist at your next appointment: what is this hospital’s protocol for reversing my anticoagulant in a rare emergency? Knowing that your local hospital uses 4F-PCC, understanding that this has been the clinical standard in most Australian centres throughout the andexanet alfa era, and understanding its scope and limitations — that is a reasonable and grounded conversation to initiate.

The system is managing this. But you are entitled to understand what managing it looks like.

Verdict

Verdict: yes — worth knowing about.

If you are on a Factor Xa inhibitor, this is not a signal to change your medication. It is a signal to understand your emergency management landscape and have a clear conversation with your prescribing doctor. The clinical picture is more nuanced than the headline reads, and the system has a fallback — it is just not the specific agent that was provisionally approved.